Switching antiretrovirals in older patients

Abstract

In The Lancet HIV, Franco Maggiolo and colleagues1 report the results of the first phase 3 randomised controlled trial (RCT) of antiretroviral therapy in people living with HIV aged 60 years or older (mean 66 years). The median age of people living with HIV enrolled in previous RCTs of first-line regimens was younger than 35 years2,3 and the median age at enrolment in RCTs of switching regimens was 40–50 years.4–6 However, in developed countries half of people living with HIV are aged 50 years or older.